FEATURED COMPANIES
- Celularity Inc.
- Gamida Cell Ltd.
- Nohla Therapeutics, Inc.
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Cancer is one of the most common causes of deaths across the world. The high prevalence of various types of cancer, such as breast cancer, bladder cancer, lung cancer, leukemia, pancreatic cancer, and prostate cancer, has increased the mortality rate across the world. Countries such as Hungary, Netherlands, Denmark, and Croatia have witnessed an increase in the number of cancer cases over the past few years. The growing instances of cancer-related morbidity across the world will fuel the demand for cancer stem cell therapeutics and drive the growth of the global cancer stem cell therapy market size at a CAGR of over 11% during the forecast period.
Market Overview
Strong drug pipeline
The prevalence of cancer across the world is driving many vendors in the market to develop novel stem cell therapies. Several drugs are in the late stages of clinical trials and are expected to receive marketing approvals over the forecast period. For instance, CanStem 303C is an orally administered drug developed to inhibit cancer cell pathways in patients with metastatic pancreatic ductal adenocarcinoma. The drug is currently in Phase III of clinical trials and is expected to be launched in the US by 2021.
Side-effects of stem cell transplant
Stem cell transplant causes several immediate side effects such as fatigue, vomiting, low levels of platelets and red blood cells, and diarrhea. It may also cause several long term effects such as infertility, eye disorders, early menopause, lung and bone damage, and risk of developing other cancer types. These risk factors may hinder the growth of the global cancer stem cell therapy market size.
Competitive Landscape
The market appears to be fairly concentrated with few players occupying the market share. Companies such as Cellerant Therapeutics Inc. and Celularity Inc. have intensified competition. Factors such as the rising prevalence of cancer and the strong drug pipeline will provide significant growth opportunities for cancer stem cell therapy companies. Cellerant Therapeutics Inc., Celularity Inc., Gamida Cell Ltd., Nohla Therapeutics Inc., and Sumitomo Dainippon Pharma Co. Ltd. are some of the major companies covered in this report.
Market Overview
Strong drug pipeline
The prevalence of cancer across the world is driving many vendors in the market to develop novel stem cell therapies. Several drugs are in the late stages of clinical trials and are expected to receive marketing approvals over the forecast period. For instance, CanStem 303C is an orally administered drug developed to inhibit cancer cell pathways in patients with metastatic pancreatic ductal adenocarcinoma. The drug is currently in Phase III of clinical trials and is expected to be launched in the US by 2021.
Side-effects of stem cell transplant
Stem cell transplant causes several immediate side effects such as fatigue, vomiting, low levels of platelets and red blood cells, and diarrhea. It may also cause several long term effects such as infertility, eye disorders, early menopause, lung and bone damage, and risk of developing other cancer types. These risk factors may hinder the growth of the global cancer stem cell therapy market size.
Competitive Landscape
The market appears to be fairly concentrated with few players occupying the market share. Companies such as Cellerant Therapeutics Inc. and Celularity Inc. have intensified competition. Factors such as the rising prevalence of cancer and the strong drug pipeline will provide significant growth opportunities for cancer stem cell therapy companies. Cellerant Therapeutics Inc., Celularity Inc., Gamida Cell Ltd., Nohla Therapeutics Inc., and Sumitomo Dainippon Pharma Co. Ltd. are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Celularity Inc.
- Gamida Cell Ltd.
- Nohla Therapeutics, Inc.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Allogeneic stem cell transplant - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Allogeneic stem cell transplant - Year-over-year growth 2019-2023 (%)
Exhibit 21: Allogeneic stem cell transplants under development
Exhibit 22: Autologous stem cell transplant - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Autologous stem cell transplant - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Late-stage cancer stem cell therapy
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Cellerant Therapeutics Inc. - Vendor overview
Exhibit 46: Cellerant Therapeutics Inc. - Key offerings
Exhibit 47: Celularity Inc. - Vendor overview
Exhibit 48: Celularity Inc. - Key offerings
Exhibit 49: Gamida Cell Ltd. - Vendor overview
Exhibit 50: Gamida Cell Ltd. - Business segments
Exhibit 51: Gamida Cell Ltd. - Key offerings
Exhibit 52: Nohla Therapeutics Inc. - Vendor overview
Exhibit 53: Nohla Therapeutics Inc. - Key offerings
Exhibit 54: Sumitomo Dainippon Pharma Co. Ltd. - Vendor overview
Exhibit 55: Sumitomo Dainippon Pharma Co. Ltd. - Business segments
Exhibit 56: Sumitomo Dainippon Pharma Co. Ltd. - Organizational developments
Exhibit 57: Sumitomo Dainippon Pharma Co. Ltd. - Segment focus
Exhibit 58: Sumitomo Dainippon Pharma Co. Ltd. - Key offerings
Exhibit 59: Validation techniques employed for market sizing
Exhibit 60: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by type
- Comparison by type
- Allogeneic stem cell transplant - Market size and forecast 2018-2023
- Autologous stem cell transplant - Market size and forecast 2018-2023
- Market opportunity by type
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Increasing research activity on cancer stem cell key signaling pathways
- Availability of stem cell markers in the identification of cancer stem cells
- Development of first-in-class therapeutics using induced pluripotent stem cells
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Cellerant Therapeutics, Inc.
- Celularity Inc.
- Gamida Cell Ltd.
- Nohla Therapeutics, Inc.
- Sumitomo Dainippon Pharma Co. Ltd.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Allogeneic stem cell transplant - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Allogeneic stem cell transplant - Year-over-year growth 2019-2023 (%)
Exhibit 21: Allogeneic stem cell transplants under development
Exhibit 22: Autologous stem cell transplant - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Autologous stem cell transplant - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Late-stage cancer stem cell therapy
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Cellerant Therapeutics Inc. - Vendor overview
Exhibit 46: Cellerant Therapeutics Inc. - Key offerings
Exhibit 47: Celularity Inc. - Vendor overview
Exhibit 48: Celularity Inc. - Key offerings
Exhibit 49: Gamida Cell Ltd. - Vendor overview
Exhibit 50: Gamida Cell Ltd. - Business segments
Exhibit 51: Gamida Cell Ltd. - Key offerings
Exhibit 52: Nohla Therapeutics Inc. - Vendor overview
Exhibit 53: Nohla Therapeutics Inc. - Key offerings
Exhibit 54: Sumitomo Dainippon Pharma Co. Ltd. - Vendor overview
Exhibit 55: Sumitomo Dainippon Pharma Co. Ltd. - Business segments
Exhibit 56: Sumitomo Dainippon Pharma Co. Ltd. - Organizational developments
Exhibit 57: Sumitomo Dainippon Pharma Co. Ltd. - Segment focus
Exhibit 58: Sumitomo Dainippon Pharma Co. Ltd. - Key offerings
Exhibit 59: Validation techniques employed for market sizing
Exhibit 60: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Celularity Inc.
- Gamida Cell Ltd.
- Nohla Therapeutics, Inc.
The following companies are recognised as the key players in the global cancer stem cell therapy market: Cellerant Therapeutics Inc., Celularity Inc., Gamida Cell Ltd., Nohla Therapeutics Inc., and Sumitomo Dainippon Pharma Co. Ltd.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing research activity on cancer stem cell key signaling pathways.”
According to the report, one of the major drivers for this market is the rising prevalence of cancer.
Further, the report states that one of the major factors hindering the growth of this market is the side-effects of stem cell transplant.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing research activity on cancer stem cell key signaling pathways.”
According to the report, one of the major drivers for this market is the rising prevalence of cancer.
Further, the report states that one of the major factors hindering the growth of this market is the side-effects of stem cell transplant.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- Cellerant Therapeutics, Inc.
- Celularity Inc.
- Gamida Cell Ltd.
- Nohla Therapeutics, Inc.
- Sumitomo Dainippon Pharma Co. Ltd.
Note: Product cover images may vary from those shown
LOADING...
